Related Experiment Video
Updated: May 23, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
Pharmacogenomics-based clinical studies using a novel, fully automated genotyping system
S Hasegawa1, S Kimura, A Kobayashi
1Research and Development, Sekino Clinical Pharmacology Clinic, Tokyo, Japan.
Drug Discoveries & Therapeutics
|April 17, 2012
Summary
This study introduces an automated genotyping system for analyzing drug metabolism genes like CYP2C19. This technology aids in classifying individuals based on their genetic makeup for personalized medicine.
Area of Science:
- Pharmacogenomics
- Molecular Diagnostics
Background:
- Single nucleotide polymorphisms (SNPs) influence drug metabolism, impacting treatment efficacy and safety.
- The CYP2C19 gene is crucial for metabolizing drugs like proton pump inhibitors, with a high prevalence of poor metabolizers in the Japanese population.
- Genetic variations in drug-metabolizing enzymes necessitate precise genotyping for clinical applications.
Purpose of the Study:
- To introduce a novel, fully automated genotyping system for SNP analysis.
- To validate the system's capability in genotyping the CYP2C19 gene.
- To demonstrate the system's potential for clinical studies involving pharmacogenetics.
Main Methods:
- Development of a fully automated system for SNP genotyping.
- Utilized fluorescence quenching probe technology for DNA melting curve analysis.
- Integrated sample preparation with automated multiple SNP genotyping.
Main Results:
- Successful implementation of a fully automated CYP2C19 genotyping system.
- The system accurately analyzes SNPs based on DNA melting curve properties.
- Demonstrated automated, high-throughput SNP analysis from sample preparation.
Conclusions:
- The novel automated system offers efficient and accurate SNP genotyping.
- This technology is suitable for clinical studies requiring pharmacogenetic classification.
- Enables precise patient stratification for personalized drug therapy based on genetic variations.
Related Concept Videos
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...